

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. )**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under Rule 14a-12

**GW PHARMACEUTICALS PLC**

(Name of Registrant as Specified In Its Charter)

**JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

---

---

---

---



Yesterday, Jazz announced a definitive agreement to acquire GW Pharmaceuticals plc, which will strengthen our position as an innovative global biopharma company by combining our strengths with an industry leader in [#cannabinoid](#) science.

Important: [bit.ly/3pOqBAU](https://bit.ly/3pOqBAU)



8:47 AM · Feb 4, 2021 · Twitter Web App



**Neena Patil**

General Counsel at Jazz Pharmaceuticals (NASDAQ: JAZZ)

2h • Edited •



We are excited about this news and our transformation journey at [Jazz Pharmaceuticals](#). Jazz and [GW Pharmaceuticals plc](#) are focused on developing life-changing medicines for people with serious diseases, often with limited or no treatment options. Patients are at the center of what each company does. Jazz's and GW's global teams possess unique talents and expertise and have proven capability to develop and launch differentiated therapies to support often-overlooked patient populations. Both companies are purpose-led and guided by shared values that include integrity, collaboration, passion, innovation and pursuit of excellence, and have cultures where diversity, equity and inclusion are a priority. Important: <https://lnkd.in/eG8NBjF>



**Jazz Pharmaceuticals**

63,269 followers

1d • Edited •

[+ Follow](#)

Today Jazz announced a definitive agreement to acquire GW Pharmaceuticals plc, a global leader in the science, development, manufacturing and commercialization of cannabinoid-based prescription medicines. [...see more](#)



“ We are joining two teams that share a passion for and track record of developing differentiated therapies that advance science and transform the lives of patients. This transaction will combine two global neuroscience companies both focused on critical, unmet patient needs. ”

**Bruce Cozadd**  
Chairman and Chief Executive Officer  
Jazz Pharmaceuticals



[Read More](#)

[investor.jazzpharma.com](https://investor.jazzpharma.com) • 14 min read